Capitalism is groovy, but at what cost?

Due to the COVID-19 pandemic, the FDA was forced to bypass normal protocol and issue Emergency Use Authorization for diagnostic testing. As a result, we have seen an explosion in the number of available molecular diagnostic tests developed by various private enterprises. Our case reports of an 85-ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Vedala, Krishna, Sobash, Phillip T, Wang, Shiyu, Kamoga, Gilbert-Roy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599026/
https://www.ncbi.nlm.nih.gov/pubmed/33194126
http://dx.doi.org/10.1080/20009666.2020.1803606
_version_ 1783602777142853632
author Vedala, Krishna
Sobash, Phillip T
Wang, Shiyu
Kamoga, Gilbert-Roy
author_facet Vedala, Krishna
Sobash, Phillip T
Wang, Shiyu
Kamoga, Gilbert-Roy
author_sort Vedala, Krishna
collection PubMed
description Due to the COVID-19 pandemic, the FDA was forced to bypass normal protocol and issue Emergency Use Authorization for diagnostic testing. As a result, we have seen an explosion in the number of available molecular diagnostic tests developed by various private enterprises. Our case reports of an 85-year-old female who was suffering from a multitude of co-morbidities and underwent three different molecular diagnostic tests in a short timeframe. With little data on the precision and reliability of the multiple available tests, it has become extremely difficult to diagnose and guide management. Instead of focusing on commercial ventures, FDA in conjunction with the CDC should prioritize our resources to tackle COVID-19 as a public health crisis.
format Online
Article
Text
id pubmed-7599026
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-75990262020-11-12 Capitalism is groovy, but at what cost? Vedala, Krishna Sobash, Phillip T Wang, Shiyu Kamoga, Gilbert-Roy J Community Hosp Intern Med Perspect Perspective Due to the COVID-19 pandemic, the FDA was forced to bypass normal protocol and issue Emergency Use Authorization for diagnostic testing. As a result, we have seen an explosion in the number of available molecular diagnostic tests developed by various private enterprises. Our case reports of an 85-year-old female who was suffering from a multitude of co-morbidities and underwent three different molecular diagnostic tests in a short timeframe. With little data on the precision and reliability of the multiple available tests, it has become extremely difficult to diagnose and guide management. Instead of focusing on commercial ventures, FDA in conjunction with the CDC should prioritize our resources to tackle COVID-19 as a public health crisis. Taylor & Francis 2020-10-29 /pmc/articles/PMC7599026/ /pubmed/33194126 http://dx.doi.org/10.1080/20009666.2020.1803606 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of Greater Baltimore Medical Center. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Perspective
Vedala, Krishna
Sobash, Phillip T
Wang, Shiyu
Kamoga, Gilbert-Roy
Capitalism is groovy, but at what cost?
title Capitalism is groovy, but at what cost?
title_full Capitalism is groovy, but at what cost?
title_fullStr Capitalism is groovy, but at what cost?
title_full_unstemmed Capitalism is groovy, but at what cost?
title_short Capitalism is groovy, but at what cost?
title_sort capitalism is groovy, but at what cost?
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599026/
https://www.ncbi.nlm.nih.gov/pubmed/33194126
http://dx.doi.org/10.1080/20009666.2020.1803606
work_keys_str_mv AT vedalakrishna capitalismisgroovybutatwhatcost
AT sobashphillipt capitalismisgroovybutatwhatcost
AT wangshiyu capitalismisgroovybutatwhatcost
AT kamogagilbertroy capitalismisgroovybutatwhatcost

Ejemplares similares